MedTrace Logo

Aerosoliserat DNase for Treatment of Respiratory Failure in Severe COVID-19

NCT04541979 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2024-08-06

No results posted yet for this study

Summary

Recent observations have suggested a role of neutrophil extracellular traps (NETs) in the pathophysiology of severe COVID-19. The aim of the study is to assess efficacy and safety of aerosolized DNase I to remove NETs and decrease respiratory distress in patients with COVID-19.

Conditions

Interventions

DRUG

aerosolized DNase

DNase

DRUG

NaCl

NaCl 0.9%, isotonic saline

Sponsors & Collaborators

  • Region Skane

    lead OTHER

Principal Investigators

  • Adam Linder, MD · Region Skåne

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-04
Primary Completion
2022-01-11
Completion
2023-01-06

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04541979 on ClinicalTrials.gov